Foundation Medicine to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (NASDAQ: FMI) today announced that members of the company's management team will present at the following upcoming investor conferences:

• Michael J. Pellini, M.D., chief executive officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015, at 2:20 p.m. P.T. in Las Vegas.
• Jason Ryan, chief financial officer, will present at the UBS Global Healthcare Conference on Monday, May 18, 2015, at 3:30 p.m. E.T. in New York City.

Live, listen-only webcasts of the presentations may be accessed by visiting the investors section of the company’s website at investors.foundationmedicine.com. Replays of the webcasts will be available shortly after the conclusion of the presentations and will be archived on the company's website for two weeks.

About Foundation Medicine

Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOne® for solid tumors and FoundationOne® Heme for hematologic malignancies and sarcomas, provide a fully informative genomic profile to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

Media Contact:
Dan Budwick, Pure Communications, Inc.
973-271-6085
[email protected]
or
Investor Contact:
Susan Hager, 617-418-2258
[email protected]
or
Matt Clawson, 949-370-8500
[email protected]

Source: Foundation Medicine, Inc.

You May Also Be Interested In

• BofA Securities Starts ProQR Therapeutics N.V. (PRQR) at Buy
• NACCO INDUSTRIES DECLARES QUARTERLY DIVIDEND
• Pivotal Health Partnership Brings IDR Expertise To More Than 350 Hospitals Nationwide